Performance of a neuro-fuzzy model in predicting weight changes of chronic schizophrenic patients exposed to antipsychotics

Molecular Psychiatry

Volumn 13, Issue 12, 2008, Pages 1129-1137

  Lan, T H ^a,b,c   Loh, E W ^b   Wu, M S ^a   Hu, T M ^a   Chou, P ^c   Lan, T Y ^b   Chiu, H J ^a,c  

^a Yuli Hospital Department of Health Taiwan   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Antipsychotics; Neuro fuzzy modeling; Schizophrenia; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ARTIFICIAL INTELLIGENCE; ARTIFICIAL NEURAL NETWORK; FEMALE; FUZZY LOGIC; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT CHANGE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; BODY WEIGHTS AND MEASURES; BRIEF PSYCHIATRIC RATING SCALE; CHRONIC DISEASE; FEMALE; FUZZY LOGIC; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 56449127168     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4002128     Document Type: Article

References (50)

1. Ramesh AN, Kambhampati C, Monson JR, Drew PJ. Artificial intelligence in medicine. Ann R Coll Surg Engl 2004; 86: 334-338.
2. Serretti A, Smeraldi E. Neural network analysis in pharmacogenetics of mood disorders. BMC Med Genet 2004; 5: 27.
3. Sproule BA, Naranjo CA, Turksen IB. Fuzzy pharmacology: theory and applications. Trends Pharmacol Sci 2002; 23: 412-417.
4. Phares DA, Halverstadt AA, Shuldiner AR, Ferrell RE, Douglass LW, Ryan AS et al. Association between body fat response to exercise training and multilocus ADR genotypes. Obes Res 2004; 12: 807-815.
5. Ang KK, Quek C. RSPOP: Rough Set-Based Pseudo Outer-Product Fuzzy Rule Identification Algorithm. Neural Comput 2005; 17: 205-243.
6. Abraham A. Adaptation of fuzzy inference system using neural, learning. In: Nedjah N, Macedo Mourelle L (eds). Fuzzy System Engineering: Theory and Practice; Studies in Fuzziness and Soft Computing, Springer Verlag: Germany, 2005, Chapter 3, pp 53-83.
7. Lin CT, Lee CSG. Neural Fuzzy Systems: A Neuro-Fuzzy Synergism to Intelligent Systems. Prentice Hall: Upper Saddle River, NJ, 1996.
8. Kosko B. Neural Networks and Fuzzy Systems: A Dynamical Systems Approach to Machine Intelligence. Prentice Hall: Englewood Cliffs, NJ, 1992.
9. Davey RC. The obesity epidemic: too much food for thought? Br J Sports Med 2004; 38: 360-363.
10. Golay A, Masciangelo ML. Burden of obesity: from epidemic to costs. Rev Med Suisse 2005; 1: 807-813.
11. Catapano L, Castle D. Obesity in schizophrenia: what can be done about it? Australas Psychiatry 2004; 12: 23-25.
12. Merriman S, Haw C, Kirk J, Stubbs J. Risk factors for coronary heart disease among inpatients who have mild intellectual disability and mental illness. J Intellect Disabil Res 2005; 49: 309-316.
13. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 2004; 47: S76-S79.
14. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003; 23: S21-S26.
15. Lin YC, Yen LL, Chen SY, Kao MD, Tzeng MS, Huang PC et al. Prevalence of overweight and obesity and its associated factors. Findings from National Nutrition and Health Survey in Taiwan, 1993-1996. Prev Med 2003; 37: 233-241.
16. Hsiao CC, Ree SC, Chiang YL, Yeh SS, Chen CK. Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan. Psychiatry Clin Neurosci 2004; 58: 403-409.
17. Lin CC, Bai YM, Wang YC, Chen JY, Liou YJ, Lin CY et al. Artificial neural network prediction of therapeutic response to clozapine with clinical and genetic factors. Eur Neuropsychopharmacol 2004; 14: 282.
18. Nie J, Linkens DA. Fuzzy-Neural Control. Prentice Hall: London, 1995.
19. Rosmond R, Bouchard C, Bjorntorp P. Increased abdominal obesity in subjects with a mutation in the 5-HT(2A) receptor gene promoter. Ann N Y Acad Sci 2002; 967: 571-575.
20. Aubert R, Betoulle D, Herbeth B, Siest G, Fumeron F. 5-HT2A receptor gene polymorphism is associated with food and alcohol intake in obese people. Int J Obes Relat Metab Disord 2000; 24: 920-924.
21. Hinney A, Ziegler A, Nothen MM, Remschmidt H, Hebebrand J. 5-HT2A receptor gene polymorphisms, anorexia nervosa, and obesity. Lancet 1997; 350: 1324-1325.
22. Santos JL, Ochoa MC, Patino A, Azcona C, Martinez JA, Marti A. No evidence of association between the serotonin 2A receptor - 1438G/A promoter polymorphism and childhood obesity in a Spanish population: a case-parent study and a matched casecontrol study. Nutr Neurosci 2005; 8: 207-211.
23. Vickers SP, Easton N, Webster LJ, Wyatt A, Bickerdike MJ, Dourish CT et al. Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 2003; 167: 274-280.
24. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007; 12: 1-8.
25. Ukkola O, Perusse L, Chagnon YC, Despres JP, Bouchard C. Interactions among the glucocorticoid receptor, lipoprotein lipase and adrenergic receptor genes and abdominal fat in the Quebec Family Study. Int J Obes Relat Metab Disord 2001; 25: 1332-1339.
26. Garenc C, Perusse L, Chagnon YC, Rankinen T, Gagnon J, Borecki IB et al. The alpha 2-adrenergic receptor gene and body fat content and distribution: the HERITAGE Family Study. Mol Med 2002; 8: 88-94.
27. Dionne IJ, Turner AN, Tchernof A, Pollin TI, Avrithi D, Gray D et al. Identification of an interactive effect of beta3- and alpha2b-adrenoceptor gene polymorphisms on fat mass in Caucasian women. Diabetes 2001; 50: 91-95.
28. Linne Y, Dahlman I, Hoffstedt J. Beta1-adrenoceptor gene polymorphism predicts long-term changes in body weight. Int J Obes Relat Metab Disord 2005; 29: 458-462.
29. Dionne IJ, Garant MJ, Nolan AA, Pollin TI, Lewis DG, Shuldiner AR et al. Association between obesity and a polymorphism in the beta(1)-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women. Int J Obes Relat Metab Disord 2002; 26: 633-639.
30. Pereira AC, Floriano MS, Mota GF, Cunha RS, Herkenhoff FL, Mill JG et al. Beta2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension 2003; 42: 685-692.
31. Martinez JA, Corbalan MS, Sanchez-Villegas A, Forga L, Marti A, Martinez-Gonzalez MA. Obesity risk is associated with carbohydrate intake in women carrying the Gln27Glu beta2-adrenoceptor polymorphism. J Nutr 2003; 133: 2549-2554.
32. Macho-Azcarate T, Marti A, Calabuig J, Martinez JA. Basal fat oxidation and after a peak oxygen consumption test in obese women with a beta2 adrenoceptor gene polymorphism. J Nutr Biochem 2003; 14: 275-279.
33. Gonzalez Sanchez JL, Proenza AM, Martinez Larrad MT, Ramis JM, Fernandez PC, Palou A et al. The glutamine 27 glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain. Clin Endocrinol 2003; 59: 476-481.
34. Lin RCY, Ericsson JO, Benjafield AV, Morris BJ. Association of beta2-adrenoceptor Gln27Glu variant with body weight but not hypertension. Am J Hypertens 2001; 14: 1201-1204.
35. Ehrenborg E, Skogsberg J, Ruotolo G, Large V, Eriksson P, Arner P et al. The Q/E27 polymorphism in the beta2-adrenoceptor gene is associated with increased body weight and dyslipoproteinaemia involving triglyceride-rich lipoproteins. J Intern Med 2000; 247: 651-656.
36. Meirhaeghe A, Helbecque N, Cottel D, Amouyel P. Impact of polymorphisms of the human beta2-adrenoceptor gene on obesity in a French population. Int J Obes Relat Metab Disord 2000; 24: 382-387.
37. Ochoa MC, Marti A, Azcona C, Chueca M, Oyarzabal M, Pelach R et al. Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents. Int J Obes Relat Metab Disord 2004; 28(Suppl 3): S37-S41.
38. Xinli W, Xiaomei T, Meihua P, Song L. Association of a mutation in the beta3-adrenergic receptor gene with obesity and response to dietary intervention in Chinese children. Acta Paediatr 2001; 90: 1233-1237.
39. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 1992; 160(Suppl 17): 12-16.
40. Hsu JW, Wang YC, Lin CC, Bai YM, Chen JY, Chiu HJ et al. No evidence for association of alpha 1a adrenoceptor gene polymorphism and clozapine-induced urinary incontinence. Neuropsychobiology 2000; 42: 62-65.
41. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62(Suppl 23): 45-66.
42. Tsai SJ, Yu YW, Lin CH, Wang YC, Chen JY, Hong CJ. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology 2004; 50: 37-40.
43. Tsai SJ, Wang YC, Yu Younger WY, Lin CH, Yang KH, Hong CJ. Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res 2001; 49: 53-58.
44. Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Byun YC et al. Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 394-397.
45. Hoehe MR, Berrettini WH, Schwinn DA, Hsieh WT. A two-allele PstI RFLP for the alpha-1C adrenergic receptor gene (ADRA1C). Hum Mol Genet 1992; 1: 349.
46. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995; 333: 348-351.
47. Lario S, Calls J, Cases A, Oriola J, Torras A, Rivera F. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet 1997; 51: 129-130.
48. Collier DA, Arranz MJ, Li T, Mupita D, Brown N, Treasure J. Association between 5-HT2A gene promoter polymorphism and anorexia nervosa. Lancet 1997; 350: 412.
49. Visscher TL, Seidell JC. Time trends (1993-1997) and seasonal variation in body mass index and waist circumference in the Netherlands. Int J Obes Relat Metab Disord 2004; 28: 1309-1316.
50. Okajima Y, Togo M, Kitagawa G, Nishikawa S. Time series analysis of monthly body weight and blood pressures of one man from 29 to 65 years. Am J Human Biol 2000; 12: 526-541.